Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.

doi:10.1136/jitc-2020-000674

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.

Journal for immunotherapy of cancer - 1 May 2020

D'Angelo Sandra P, Bhatia Shailender, Brohl Andrew S, Hamid Omid, Mehnert Janice M, Terheyden Patrick, Shih Kent C, Brownell Isaac, Lebbé Celeste, Lewis Karl D, Linette Gerald P, Milella Michele, Georges Sara, Shah Parantu, Ellers-Lenz Barbara, Bajars Marcis, Güzel Gülseren, Nghiem Paul T

Abstract excerpt

BACKGROUND: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with a high risk of metastasis. In 2017, avelumab (anti-programmed death-ligand 1 (PD-L1)) became the first approved treatment for patients with metastatic MCC (mMCC), based on the occurrence of durable responses in a subset of patients. Here, we report long-term efficacy and safety data and exploratory biomarker analyses in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Carcinoma, Merkel Cell

Share to Histocompatibility Antigens Class I

Share to Immune Checkpoint Inhibitors

Share to Progression-Free Survival

Share to Skin

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 32414862
DOI: 10.1136/jitc-2020-000674
PMCID: PMC7239697

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.PMID 32414862Read ↗

Biomarker Analyses Investigating Disease Biology and Associations with Outcomes in the JAVELIN Merkel 200 Trial of Avelumab in Metastatic Merkel Cell Carcinoma.Semantic proximity Read ↗

Merkel cell carcinoma.Semantic proximity Read ↗

miRNAs driving diagnosis, prognosis and progression in Merkel cell carcinomaSemantic proximity Read ↗

Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial.Semantic proximity Read ↗

[Clinical studies and accepted therapies of advanced melanoma].Semantic proximity Read ↗

Delta-Like Protein 3 Expression and Targeting in Merkel Cell CarcinomaSemantic proximity Read ↗

Merkel Cell Carcinoma Patients Presenting Without a Primary Lesion Have Elevated Markers of Immunity, Higher Tumor Mutation Burden, and Improved Survival.Semantic proximity Read ↗

Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMECSemantic proximity Read ↗

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma.Semantic proximity Read ↗

BRCA1/2 Pathogenic Variants Are Not Common in Merkel Cell Carcinoma: Comprehensive Molecular Study of 30 Cases and Meta-Analysis of the Literature.Semantic proximity Read ↗

Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma.Semantic proximity Read ↗

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.